within Pharmacolibrary.Drugs.ATC.C;

model C02LG03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 1.0,
    adminDuration  = 600,
    adminMass      = 0.025,
    adminCount     = 1,
    Vd             = 0.08,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Picodralazine is a vasodilator antihypertensive agent, usually combined with diuretics for the management of high blood pressure. It is classified under the ATC code C02LG03. The combination is used to lower blood pressure in patients where monotherapy is insufficient. Picodralazine is not widely used today and is not approved in most modern formularies.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic parameters specific to picodralazine and diuretics combination have been identified in the literature for any subgroup of patients. Parameters below are estimated based on typical pharmacokinetics for similar antihypertensive vasodilators administered orally in adults.</p><h4>References</h4><ol><li><p>Felker, GM, et al., &amp; O&#x27;Connor, CM (2011). Diuretic strategies in patients with acute decompensated heart failure. <i>The New England journal of medicine</i> 364(9) 797–805. DOI:<a href=&quot;https://doi.org/10.1056/NEJMoa1005419&quot;>10.1056/NEJMoa1005419</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21366472/&quot;>https://pubmed.ncbi.nlm.nih.gov/21366472</a></p></li><li><p>Hoorn, EJ, &amp; Ellison, DH (2017). Diuretic Resistance. <i>American journal of kidney diseases : the official journal of the National Kidney Foundation</i> 69(1) 136–142. DOI:<a href=&quot;https://doi.org/10.1053/j.ajkd.2016.08.027&quot;>10.1053/j.ajkd.2016.08.027</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27814935/&quot;>https://pubmed.ncbi.nlm.nih.gov/27814935</a></p></li><li><p>Verbeeck, RK (2008). Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. <i>European journal of clinical pharmacology</i> 64(12) 1147–1161. DOI:<a href=&quot;https://doi.org/10.1007/s00228-008-0553-z&quot;>10.1007/s00228-008-0553-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18762933/&quot;>https://pubmed.ncbi.nlm.nih.gov/18762933</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C02LG03;
